a3rd Department of Internal Medicine, Hypertension-24-h ABPM ESH Center of Excellence, Papageorgiou Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece
bInstitute for Aerospace Medicine, German Aerospace Center, University of Cologne
cUniversity Hypertension Center, Cologne, Germany
d1st Department of Pediatrics, Aristotle University of Thessaloniki, Hippokratio General Hospital, Thessaloniki, Greece
eDepartment of Medical Sciences, Serbian Academy of Sciences and Arts, Belgrade, Serbia
fDepartment of Nephrology, Hypertension, Dialysis and Transplantation, University Hospital Centre Zagreb, Zagreb, Croatia
gDobney Hypertension Centre, School of Medicine – Royal Perth Hospital Unit, The University of Western Australia, Perth, Western Australia
hNeurovascular Hypertension and Kidney Disease Laboratory, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia
iDepartment of Clinical Sciences, Internal Medicine, Skåne University Hospital, Malmö, Sweden
jCharité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin
kInstitute of Clinical Pharmacology and Toxicology, Berlin, Germany
lUniversity of Milano-Bicocca, Milan, Italy
mFirst Cardiology Clinic, Medical School, National and Kapodistrian University of Athens Hippokration Hospital, Athens, Greece
nClinical Medica, School of Medicine and Surgery, Milano-Bicocca University
oIRCCS Multimedica, Sesto San Giovanni, Milan, Italy
Correspondence to Vasilios Kotsis, MD, PhD, Hypertension-ABPM Center, Papageorgiou Hospital, Chairman WG on Obesity, Diabetes and the High Risk Patient, 39 Zaka, Panorama, 55236 Thessaloniki, Greece. Tel: +30 6974748860; fax: +30 2310452429; e-mail: vkotsis@auth.gr
Abbreviations: ALT, alanine transaminase; BP, blood pressure; DPP-4, dipeptidyl peptidase-4; GLP-1, glucagon-like peptide 1; MACE, major adverse cardiac events; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; RAAS, renin–angiotensin–aldosterone system; SGLT-2, sodium–glucose cotransporter 2; T2D, type 2 diabetes
Received 10 June, 2019
Revised 23 August, 2019
Accepted 16 September, 2019
